Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MR-1817
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MR-1817 is a small molecule drug that acts as an antagonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the vanilloid receptor. It was developed for oral administration primarily for the treatment of pain. The drug was initially developed by Pfizer and later by Mochida Pharmaceutical, with clinical development reaching phase 1 trials in healthy volunteers. As a TRPV1 antagonist, MR-1817 targets pathways involved in pain signaling and neurogenic inflammation, aiming to provide analgesic effects without opioid-related side effects[1][2][4][7].
- Other names
- VRA-175VRA175VRA 175
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on MR-1817.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MR-1817.